TBPH - Theravance Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
19.65
-0.19 (-0.96%)
At close: 4:00PM EDT

19.65 0.00 (0.00%)
After hours: 4:39PM EDT

Stock chart is not supported by your current browser
Previous Close19.84
Open19.95
Bid19.61 x 800
Ask25.75 x 1000
Day's Range19.20 - 20.33
52 Week Range19.20 - 35.48
Volume262,383
Avg. Volume266,216
Market Cap1.103B
Beta (3Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire16 hours ago

    Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019

    Numerically higher rates of clinical response were observed for TD-1473 after four weeks of treatment as compared to placebo. Clinical response, which was defined as a reduction in total Mayo score of ≥ 3 points and ≥ 30%, with a reduction in rectal bleeding subscore by ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point, was achieved by 2 of 10 patients (20%) in the 20 mg cohort, 2 of 10 patients (20%) in the 80 mg cohort, and 6 of 11 patients (55%) in the 270 mg cohort, compared to 1 of 9 patients (11%) in placebo group.

  • PR Newswire2 days ago

    Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society (ATS) International Conference in Dallas, Texas. YUPELRI® (revefenacin) inhalation solution, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the U.S.

  • PR Newswire8 days ago

    Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019

    DUBLIN, May 14, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that results from the Company's Phase 1b study of TD-1473 in patients with moderately-to-severely active ulcerative colitis will be the focus of an oral presentation at Digestive Disease Week (DDW) 2019.  The presentation will highlight final data from the Phase 1b clinical trial of TD-1473 in patients with moderately-to-severely active ulcerative colitis.  These findings demonstrate signals of clinical and biomarker activity for TD-1473 suggesting localized target engagement, as well as minimal systemic exposure and no evidence of systemic immunosuppression or infections.  DDW 2019 is being held May 18-21, 2019 in San Diego, CA.

  • PR Newswire14 days ago

    Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

    - Late-stage clinical studies of TD-1473 and ampreloxetine underway - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in third quarter ...

  • PR Newswire21 days ago

    Theravance Biopharma to Report First Quarter 2019 Financial Results on May 7

    DUBLIN, Ireland, April 30, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended March 31, 2019 and provide a business update after market close on Tuesday, May 7, 2019. To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 9890346. A replay of the conference call will be available on Theravance Biopharma's website for 30 days through June 6, 2019.

  • PR Newswire2 months ago

    Theravance Biopharma to Present at the 18th Annual Needham Healthcare Conference

    DUBLIN, Ireland , April 2, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the 18 th Annual Needham Healthcare ...

  • PR Newswire2 months ago

    Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress

    DUBLIN, March 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) have been selected for an oral presentation at the 32nd European Neurology Congress. Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) in development for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH).

  • PR Newswire2 months ago

    Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis

    DUBLIN, March 12, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2b/3 study of TD-1473 in patients with moderately to severely active ulcerative colitis. TD-1473 is a novel, orally administered and gut-selective pan-Janus kinase (JAK) inhibitor in clinical development as a treatment for multiple inflammatory intestinal diseases. In contrast to other oral JAK inhibitors under development or approved for inflammatory bowel disease, TD-1473 is specifically designed to act locally at the site of inflammation in the intestinal wall with minimal systemic exposure.

  • PR Newswire3 months ago

    Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    YUPELRI™ (revefenacin) inhalation solution product launch progressing in partnership with Mylan Ampreloxetine and TD-1473 late-stage clinical programs advancing DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Theravance ...

  • ACCESSWIRE3 months ago

    Theravance Biopharma Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Theravance Biopharma Inc (NASDAQ: TBPH ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 ...

  • PR Newswire3 months ago

    Theravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    DUBLIN, Feb. 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that management will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019, at 9:00 a.m. ET. The conference will take place February 27 – March 1 at the Lotte New York Palace Hotel. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab.

  • PR Newswire3 months ago

    /C O R R E C T I O N -- Theravance Biopharma, Inc./

    In the news release, Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26, issued 19-Feb-2019 by Theravance Biopharma, Inc. over PR Newswire, we are advised by the company that date in the second paragraph, first sentence, should read "February 26, 2019" rather than "November 6, 2018" as originally issued inadvertently. DUBLIN, Feb. 19, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2018 and provide a business update after market close on Tuesday, February 26, 2019. An accompanying conference call will be held at 5:00 pm ET on February 26, 2019.  To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 8086288.

  • PR Newswire4 months ago

    Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension

    DUBLIN, Jan. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a registrational Phase 3 clinical trial of ampreloxetine (TD-9855) in patients with symptomatic neurogenic orthostatic hypotension (nOH). Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) in development for the treatment of patients with symptomatic nOH.

  • PR Newswire4 months ago

    Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities

    DUBLIN, Jan. 7, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced a reduction in workforce to align with its focus on continued execution of key strategic programs, and advancement of selected late-stage research programs toward clinical development. Theravance Biopharma will reduce its overall headcount by approximately 50 individuals, with affected employees primarily focused on early research or the infrastructure in support of VIBATIV® (telavancin). VIBATIV is a marketed antibiotic recently sold by the Company to Cumberland Pharmaceuticals, Inc.

  • PR Newswire6 months ago

    Theravance Biopharma to Highlight Innovative Early Research and Clinical Development at R&D Day on December 12 in New York

    DUBLIN, Dec. 4, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ET on Wednesday, December 12, 2018, in New York City. Theravance Biopharma management and R&D teams will provide an overview of the Company's research and development strategy, plus clinical programs and emerging research projects in therapeutic areas such as inflammatory intestinal diseases, autonomic disorders, severe asthma, lung transplant rejection, idiopathic pulmonary fibrosis, and diabetic macular edema.

  • PR Newswire6 months ago

    Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes

    DUBLIN, Dec. 3, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company") today announced the closing of a private placement of $250 million of non-recourse PhaRMASM  9% fixed rate term notes. The notes are secured by a portion of the future payments the Company expects to receive related to royalties due on net sales of Trelegy Ellipta. The Company intends to use the net proceeds from this transaction to support continued execution of its key strategic programs.

  • PR Newswire6 months ago

    Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor

    DUBLIN, Nov. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first subject in a Phase 1 clinical trial of TD-8236, a novel, inhaled, lung-selective pan-Janus kinase (JAK) inhibitor which has demonstrated potency in preclinical assessments. The Company is developing TD-8236 as an investigational compound with the potential to treat a range of serious respiratory diseases. TD-8236 is an internally-discovered JAK inhibitor that has demonstrated a high affinity and selectivity for each of the JAK family enzymes (JAK1, JAK2, JAK3 and TYK2).

  • PR Newswire6 months ago

    Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease

    DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease. TD-1473 is a novel, potent, orally administered and gut-selective pan-Janus kinase (JAK) inhibitor in development as a treatment for multiple inflammatory intestinal diseases.

  • PR Newswire6 months ago

    Theravance Biopharma to Present at Two Upcoming Investor Conferences

    The conference will be held November 27 - 29 at the Boston Harbor Hotel. The conference will be held November 27 - 29 at the Lotte New York Palace Hotel. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab.

  • GlobeNewswire6 months ago

    New Research Coverage Highlights Nexa Resources S.A, Qumu, Clearway Energy, Vermillion, Cantel Medical, and Theravance Biopharma — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire6 months ago

    Theravance Biopharma Highlights Expanded COPD Indication for Trelegy Ellipta in Europe

    DUBLIN, Nov. 12, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted that the European Commission authorized an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), recognizing the product's effect on exacerbations and making it the first single-inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innoviva (formerly Theravance, Inc.).

  • PR Newswire6 months ago

    Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI™ (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease

    DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the  New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US. The companies expect YUPELRI to be available to COPD patients in the US before the end of the year.

  • PR Newswire6 months ago

    Theravance Biopharma to Present at the Credit Suisse 27th Annual Healthcare Conference

    DUBLIN, Nov. 7, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that management will present a corporate overview at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018, at 8:35 a.m. MST.  The conference will be held from November 12 - 15 at the Phoenician in Scottsdale, AZ. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Theravance Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.

  • PR Newswire6 months ago

    Theravance Biopharma, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update

    PDUFA date for YUPELRI™ (revefenacin) inhalation solution on November 13 TD-1473 and TD-9855 entering late-stage clinical development programs; TD-8236 advancing from research into clinic Company to host ...